Sector Update: Biotechs Lift Health Care Stocks to Large Gain
3:55PM ET 6/07/2019 MT NewswiresTop Health Care Stocks JNJ +1.70% PFE +0.80% ABT +1.07% MRK +1.38% AMGN +0.67% Health care stocks were ending near their session highs, with the NYSE...
Quotes Snapshot > VRTX
Vertex Pharmaceuticals Inc VRTX:NASDAQ
Last Price$183.38Cboe Real-Time Last Sale as of 1:32PM ET 6/20/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.63(0.90%)
Bid (Size)$183.24 (32)
Ask (Size)$183.43 (100)
Day Low / High$181.27 - 186.33
Volume553.9 K
Read more news Recent News
Sector Update: Health Care Stocks Climbing More Than 1% as a Group
1:59PM ET 6/07/2019 MT NewswiresTop Health Care Stocks JNJ +1.71% PFE +0.82% ABT +0.77% MRK +1.35% AMGN +0.32% Health care stocks were posting large gains, including a 1.3% advance...
Vertex Pharmaceuticals Expands Collaboration with CRISPR, Buys Exonics Therapeutics
11:00PM ET 6/06/2019 MT NewswiresVertex Pharmaceuticals (VRTX) said it expanded its collaboration with CRISPR Therapeutics (CRSP) and acquired Exonics Therapeutics to enhance its gene...
Vertex Pharma to Seek Approvals for Triple Combination of VX-445, Tezacaftor and Ivacaftor in Cystic Fibrosis - Stock Up 2%
1:29PM ET 5/30/2019 MT NewswiresVertex Pharmaceuticals (VRTX) said on Thursday it has selected the triple combination of the next-generation corrector VX-445, tezacaftor and ivacaftor to...
View all Commentary and Analysis
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
8:38AM ET 6/20/2019 ZacksThe Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
Top Stock Reports for Deere, Las Vegas Sands & Vertex
1:02PM ET 6/19/2019 ZacksTop Stock Reports for Deere, Las Vegas Sands & Vertex
Vertex Makes Strong Push Into Crispr Tech With 2 Deals At Once
4:31PM ET 6/17/2019 Seeking AlphaBIIB Is For Buy-O-Gen
10:30AM ET 6/12/2019 Seeking AlphaCompany Profile
Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
| Address | 50 Northern Avenue Boston, Massachusetts 02210 |
| Phone | +1.617.341.6100 |
| Number of Employees | 2,500 |
| Recent SEC Filing | 06/07/2019 8-K |
| Chairman, President & Chief Executive Officer | Jeffrey M. Leiden |
| Chief Financial Officer & Executive Vice President | Charles F. Wagner |
| Chief Scientific Officer & EVP-Global Research | David Matthew Altshuler |
| Chief Medical Officer & Executive Vice President | Reshma Kewalramani |
Company Highlights
| Price Open | $183.52 |
| Previous Close | $181.75 |
| 52 Week Range | $145.37 - 195.81 |
| Market Capitalization | $47.0 B |
| Shares Outstanding | 256.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 07/24/2019 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 21.90 |
| Earnings per Share | $8.37 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.0 B |
| Net Profit Margin | 66.24% |
| Return on Equity | 58.43% |
Analyst Ratings as of 06/07/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |